Search Browse Earnings

Evolus, Inc. — SlamSEC

Evolus, Inc.

Nasdaq:EOLS

Pharmaceutical Preparations·NEWPORT BEACH, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$202.1M

+36.0% YoY

FY 2025

Adj. EBITDA

-$44.1M

-21.8% margin

FY 2025

Net Income

-$61.7M

-30.5% margin

FY 2025

EPS (Diluted)

-$1.08

FY 2025

Stock Price

$5.35

-3.4%

2026-03-09

52W Range

$4.09 – $13.66

P/E Ratio

-5.0x

Market Cap

$348.1M

Cash

$87.0M

FY 2025

Total Debt

$138.7M

FY 2019

Net Debt

$51.7M

FY 2019

Enterprise Value

$399.8M

Debt / EBITDA

-1.2x

FY 2025

EV / EBITDA

-9.1x

Employees

—

CFO

Mitchell Tatjana